ECSP20054822A - Composición anticonceptiva con efectos cardiovasculares reducidos - Google Patents
Composición anticonceptiva con efectos cardiovasculares reducidosInfo
- Publication number
- ECSP20054822A ECSP20054822A ECSENADI202054822A ECDI202054822A ECSP20054822A EC SP20054822 A ECSP20054822 A EC SP20054822A EC SENADI202054822 A ECSENADI202054822 A EC SENADI202054822A EC DI202054822 A ECDI202054822 A EC DI202054822A EC SP20054822 A ECSP20054822 A EC SP20054822A
- Authority
- EC
- Ecuador
- Prior art keywords
- thromboembolism
- cardiovascular effects
- reduced
- reduced risk
- reduced cardiovascular
- Prior art date
Links
- 239000003433 contraceptive agent Substances 0.000 title abstract 3
- 230000002254 contraceptive effect Effects 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 208000005189 Embolism Diseases 0.000 abstract 3
- 208000001435 Thromboembolism Diseases 0.000 abstract 3
- 206010014522 Embolism venous Diseases 0.000 abstract 2
- 208000004043 venous thromboembolism Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940124558 contraceptive agent Drugs 0.000 abstract 1
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 abstract 1
- 229950009589 estetrol Drugs 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000000757 progestagenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere a un método anticonceptivo con efectos cardiovasculares reducidos, tal como riesgo reducido de tromboembolismo, tal como riesgo reducido de tromboembolismo 5 venoso (TEV) y riesgo reducido de tromboembolismo aórtico (TEA). El método de la invención comprende administrar a un mamífero hembra una cantidad efectiva de un componente estetrol en combinación con un componente progestogénico. El método goza de un perfil favorable para la tromboembolia en 10 comparación con los métodos disponibles actualmente que emplean anticonceptivos de la llamada segunda, tercera o cuarta generación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155571 | 2018-02-07 | ||
| EP18160586 | 2018-03-07 | ||
| PCT/EP2019/052980 WO2019154899A1 (en) | 2018-02-07 | 2019-02-07 | Contraceptive composition with reduced cardiovascular effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20054822A true ECSP20054822A (es) | 2020-12-31 |
Family
ID=65278388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202054822A ECSP20054822A (es) | 2018-02-07 | 2020-09-04 | Composición anticonceptiva con efectos cardiovasculares reducidos |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP3749327A1 (es) |
| JP (2) | JP2021513507A (es) |
| KR (1) | KR102717921B1 (es) |
| CN (2) | CN115429806A (es) |
| AU (1) | AU2019219070B2 (es) |
| CA (2) | CA3089804A1 (es) |
| CL (1) | CL2020002017A1 (es) |
| EC (1) | ECSP20054822A (es) |
| GE (2) | GEAP202215414A (es) |
| IL (1) | IL276584B2 (es) |
| JO (1) | JOP20200169A1 (es) |
| MA (1) | MA51733A (es) |
| NZ (1) | NZ766027A (es) |
| PH (1) | PH12020500601A1 (es) |
| PY (1) | PY1908892A (es) |
| SG (1) | SG11202007163WA (es) |
| TW (1) | TWI845496B (es) |
| UA (1) | UA126746C2 (es) |
| UY (1) | UY38075A (es) |
| WO (1) | WO2019154899A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| MA44206B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
| CU24523B1 (es) | 2015-06-18 | 2021-06-08 | Estetra Sprl | Unidad de dosificación orodispersable que contiene un componente estetrol |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| EP3781171B1 (en) | 2018-04-19 | 2022-02-09 | Estetra SRL | Compounds and their uses for alleviating menopause-associated symptoms |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022248733A1 (en) | 2021-05-28 | 2022-12-01 | Neuralis Sa | Use of estetrol in treatment of respiratory infection diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| DK1390042T3 (da) * | 2001-05-23 | 2008-03-31 | Pantarhei Bioscience Bv | System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| EP2432474A1 (de) * | 2009-05-22 | 2012-03-28 | Bayer Pharma Aktiengesellschaft | Arzneimittel zur oralen verabreichung, enthaltend mindestens ein estrogen und/oder mindestens ein gestagen und mindestens einen probiotischen bakterien-stamm |
| WO2012055840A1 (en) * | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
| DK3079671T3 (en) * | 2013-12-12 | 2017-12-11 | Donesta Bioscience B V | Orally disintegrating solid dosage unit containing an estetrol component |
| CA3178291A1 (en) * | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| KR102780201B1 (ko) | 2016-10-28 | 2025-03-12 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
-
2019
- 2019-02-07 IL IL276584A patent/IL276584B2/en unknown
- 2019-02-07 GE GEAP202215414A patent/GEAP202215414A/en unknown
- 2019-02-07 CA CA3089804A patent/CA3089804A1/en active Pending
- 2019-02-07 EP EP19703103.2A patent/EP3749327A1/en active Pending
- 2019-02-07 NZ NZ766027A patent/NZ766027A/en unknown
- 2019-02-07 AU AU2019219070A patent/AU2019219070B2/en active Active
- 2019-02-07 WO PCT/EP2019/052980 patent/WO2019154899A1/en not_active Ceased
- 2019-02-07 EP EP22199066.6A patent/EP4140489A1/en active Pending
- 2019-02-07 JP JP2020538823A patent/JP2021513507A/ja active Pending
- 2019-02-07 JO JOP/2020/0169A patent/JOP20200169A1/ar unknown
- 2019-02-07 UY UY38075A patent/UY38075A/es not_active Application Discontinuation
- 2019-02-07 PY PY201901908892A patent/PY1908892A/es unknown
- 2019-02-07 KR KR1020207025456A patent/KR102717921B1/ko active Active
- 2019-02-07 GE GEAP201915414A patent/GEP20227407B/en unknown
- 2019-02-07 MA MA051733A patent/MA51733A/fr unknown
- 2019-02-07 UA UAA202005421A patent/UA126746C2/uk unknown
- 2019-02-07 CA CA3178181A patent/CA3178181A1/en active Pending
- 2019-02-07 CN CN202211257175.1A patent/CN115429806A/zh active Pending
- 2019-02-07 SG SG11202007163WA patent/SG11202007163WA/en unknown
- 2019-02-07 CN CN201980012248.0A patent/CN111683664A/zh active Pending
- 2019-02-11 TW TW108104465A patent/TWI845496B/zh active
-
2020
- 2020-07-13 PH PH12020500601A patent/PH12020500601A1/en unknown
- 2020-07-31 CL CL2020002017A patent/CL2020002017A1/es unknown
- 2020-09-04 EC ECSENADI202054822A patent/ECSP20054822A/es unknown
-
2023
- 2023-09-28 JP JP2023168039A patent/JP7651645B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102717921B1 (ko) | 2024-10-16 |
| MA51733A (fr) | 2020-12-16 |
| IL276584A (en) | 2020-09-30 |
| PY1908892A (es) | 2019-10-15 |
| GEAP202215414A (en) | 2022-04-25 |
| AU2019219070B2 (en) | 2024-12-19 |
| IL276584B2 (en) | 2024-10-01 |
| CN111683664A (zh) | 2020-09-18 |
| CL2020002017A1 (es) | 2020-12-04 |
| WO2019154899A1 (en) | 2019-08-15 |
| PH12020500601A1 (en) | 2021-05-17 |
| UY38075A (es) | 2019-10-01 |
| SG11202007163WA (en) | 2020-08-28 |
| JOP20200169A1 (ar) | 2020-07-07 |
| CA3178181A1 (en) | 2019-08-15 |
| KR20200118464A (ko) | 2020-10-15 |
| JP2024009834A (ja) | 2024-01-23 |
| JP2021513507A (ja) | 2021-05-27 |
| JP7651645B2 (ja) | 2025-03-26 |
| NZ766027A (en) | 2026-03-27 |
| EP4140489A1 (en) | 2023-03-01 |
| IL276584B1 (en) | 2024-06-01 |
| CN115429806A (zh) | 2022-12-06 |
| EP3749327A1 (en) | 2020-12-16 |
| UA126746C2 (uk) | 2023-01-18 |
| AU2019219070A1 (en) | 2020-09-24 |
| GEP20227407B (en) | 2022-08-25 |
| CA3089804A1 (en) | 2019-08-15 |
| TWI845496B (zh) | 2024-06-21 |
| TW202011967A (zh) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002017A1 (es) | Composición anticonceptiva con efectos cardiovasculares reducidos. | |
| MX2018011348A (es) | Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades. | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MX2019007586A (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| CO2019000672A2 (es) | Procedimiento de tratamiento de dismenorrea y dolor menstrual | |
| MX2021013582A (es) | Composiciones que comprenden agentes biologicamente activos y sales biliares. | |
| CL2011000513A1 (es) | Metodos para reducir o inhibir la angiogenesis en un sujeto que tiene una enfermedad o condicion ocular asociada con la angiogenesis que comprende la administracion de un antagonista de tetraspanina 12(tspan12) y/o un antagonista de norrina. | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| GEP20227396B (en) | Compounds and their uses for alleviating menopause-associated symptoms | |
| MX2021005801A (es) | Metodos para administrar corticosteroides. | |
| CO2017011046A2 (es) | Prenda absorbente con buen ajuste | |
| MX2019002880A (es) | Proceso para elaborar una composicion que comprende particulas de suministro de agente benefico. | |
| AR101236A1 (es) | Composiciones para el cuidado oral | |
| BR112017010933A2 (pt) | composição farmacêutica | |
| CL2021001096A1 (es) | Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) | |
| CO2020005366A2 (es) | Composición plaguicida que contiene tidiazurón y ácido poliglutámico | |
| CL2019000174A1 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d. | |
| MX384303B (es) | Composiciones y métodos para metabolismo muscular mejorado. | |
| CL2021001397A1 (es) | Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva | |
| MX2020005037A (es) | Métodos y sistemas para planteamientos de continuidad sinérgica para el tratamiento y conservación de células biológicas. | |
| AR114357A1 (es) | Composiciones anticonceptivas con efectos cardiovasculares reducidos | |
| MX2020002278A (es) | Metodos para el tratamiento de enfermedades relacionadas con tnfa. | |
| EA202091811A1 (ru) | Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы |